Glaukos (GKOS) 44th Annual J.P. Morgan Healthcare Conference summary

Business innovation and product development

• Focus on innovation has led to leadership in MIGS and creation of new markets in ophthalmology, including procedural pharmaceuticals and corneal cross-linking.

• Over $800 million invested in R&D since 2018, resulting in 12 commercial products and 13 in development.

• Platforms like iStent, iDose, iLink, and iLution drive cascades of new products and address unmet clinical needs.

• Sustained over 20% CAGR for 10 years, with a record quarter and 30% market growth recently.

• Expansion into rare diseases and transdermal therapies, with plans to build a retinal company.

Glaucoma treatment paradigm and product pipeline

• Current glaucoma treatment is seen as outdated; focus is on interventional approaches for better adherence and outcomes.

• iDose TR offers sustained intraocular pressure reduction, with 81% of patients off all medications at one year and 70% well controlled at three years.

• New products like iDose Trio and iDose TREX aim to extend duration and facilitate in-office use, with clinical trials underway.

• iStent infinite demonstrated superior safety and efficacy in trials, with plans to expand indications by 2027.

• Market opportunity includes 12 million diagnosed eyes, with potential for multiple interventions per patient over 20 years.

Commercial strategy and market expansion

• Combination therapy (iDose with iStent) is being studied for additive effects.

• In-office injectable therapy and repeat administration approvals are expected to drive adoption.

• Vision for 2035 includes as many interventional glaucoma procedures as cataract surgeries.

• Full product portfolio covers all stages of glaucoma, aiming for best benefit-to-risk ratio.